Aurinia Pharmaceuticals (AUPH) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights
May 14, 2020 4:02 PM EDT- Cash and cash equivalents totaled approximately $286 million at March 31, 2020 -
- Rolling submission of voclosporin New Drug Application to the U.S. Food & Drug Administration remains on track for completion by the end of the second quarter 2020
- Continued evolution into commercial-stage organization highlighted by the appointments of Timothy P Walbert to the Board, Max Colao as Chief Commercial Officer, and Joe Miller as Chief Financial Officer
- Conference call and webcast to be hosted today at 4:30pm EDT -
VICTORIA, British... More
